Wednesday, 22 February 2012



ACTIVE PHARMACEUTICAL INGREDIENTS (API)

" A substance used in a finished pharmaceutical product (FPP), intended to furnish
pharmacological activity or to otherwise have direct effect in the diagnosis, cure,
mitigation, treatment or prevention of disease, or to have direct effect in restoring,
correcting or modifying physiological functions in human beings."

The manufacture of products based on small-molecule Active Pharmaceutical Ingredients (API) remains critical to global healthcare. The manufacturing landscape is also full of challenges and opportunities. This is due to emerging international markets and rapidly evolving social, economic, regulatory and environmental expectations. 

Enmark with its range of products and services is well positioned to help Active Pharmaceutical Ingredient customers in all stages of development and manufacturing optimization. We have many years' experience helping our clients respond to changing demands or to bring new products and processes to success in the following ways: 

Enmark offers an unparalleled portfolio to our customers comprising of innovators and generic formulators. We have a very strong product portfolio of products, and our GIVE THE BEST approach makes a fast growing API supplier all over INDIA. Our goal is to enable customers to be the first-to-launch a generic product as well as provide value-added services that help them remain competitive and profitable for the entire life cycle of the product. We have built the capabilities to consistently deliver on this promise in scale and across the largest product range. Our services have been the best as far as supplying the API to the clients is concerned.  

Enmark is growing very fast and has become the first choice of buying API for generic and Innovator companies. 

Our products range from simple analgesics, anti-inflammatory to Anti-cancer drugs, Anti TB drugs. We have wide range of API and other chemicals in our product range. 


We provide the best quality product to our clients. 

No comments:

Post a Comment